Equities research analysts expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will report earnings per share of ($1.24) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Flexion Therapeutics’ earnings. The highest EPS estimate is ($1.14) and the lowest is ($1.35). Flexion Therapeutics reported earnings of ($1.07) per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 15.9%. The business is scheduled to report its next quarterly earnings report on Monday, November 5th.

According to Zacks, analysts expect that Flexion Therapeutics will report full year earnings of ($4.75) per share for the current year, with EPS estimates ranging from ($4.92) to ($4.63). For the next financial year, analysts forecast that the company will report earnings of ($2.74) per share, with EPS estimates ranging from ($3.31) to ($1.53). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.06. The business had revenue of $3.80 million for the quarter, compared to analysts’ expectations of $3.96 million.

A number of equities analysts have recently issued reports on FLXN shares. ValuEngine upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 2nd. Benchmark started coverage on shares of Flexion Therapeutics in a research report on Thursday, June 28th. They set a “buy” rating and a $39.00 target price on the stock. BidaskClub upgraded shares of Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 14th. Finally, Zacks Investment Research upgraded shares of Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $91.50.

In related news, CEO Michael D. Clayman purchased 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The stock was purchased at an average cost of $22.33 per share, with a total value of $223,300.00. Following the completion of the acquisition, the chief executive officer now directly owns 75,282 shares in the company, valued at $1,681,047.06. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO David Arkowitz purchased 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 9th. The shares were bought at an average cost of $23.42 per share, with a total value of $93,680.00. Following the completion of the acquisition, the chief financial officer now owns 44,250 shares of the company’s stock, valued at $1,036,335. The disclosure for this purchase can be found here. 14.59% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of FLXN. Redmile Group LLC acquired a new stake in shares of Flexion Therapeutics during the first quarter worth $223,000. Stifel Financial Corp acquired a new stake in shares of Flexion Therapeutics during the first quarter worth $293,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Flexion Therapeutics during the first quarter worth $341,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Flexion Therapeutics during the first quarter worth $381,000. Finally, Wexford Capital LP acquired a new stake in shares of Flexion Therapeutics during the first quarter worth $401,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Shares of FLXN traded down $0.44 during mid-day trading on Tuesday, reaching $18.43. 1,182,641 shares of the company’s stock were exchanged, compared to its average volume of 445,828. The company has a debt-to-equity ratio of 0.80, a quick ratio of 12.78 and a current ratio of 12.90. Flexion Therapeutics has a 52-week low of $18.35 and a 52-week high of $32.25.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Story: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.